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Abstract: Accumulating evidence demonstrates that dietary supplementation with functional food
ingredients play a role in systemic and brain health as well as in healthy ageing. Conversely,
deficiencies in calcium and magnesium as a result of the increasing prevalence of a high fat/high
sugar “Western diet” have been associated with health problems such as obesity, inflammatory bowel
diseases, and cardiovascular diseases, as well as metabolic, immune, and psychiatric disorders. It is
now recognized that modulating the diversity of gut microbiota, the population of intestinal bacteria,
through dietary intervention can significantly impact upon gut health as well as systemic and brain
health. In the current study, we show that supplementation with a seaweed and seawater-derived
functional food ingredient rich in bioactive calcium and magnesium (0.1% supplementation) as well
as 70 other trace elements, significantly enhanced the gut microbial diversity in adult male rats. Given
the significant impact of gut microbiota on health, these results position this marine multi-mineral
blend (MMB) as a promising digestive-health promoting functional food ingredient.
Keywords: marine extract; calcium; magnesium; gut microbial diversity; rat
1. Introduction
The increasing prevalence of a high fat/high sugar “Western diet” has been linked to the
emergence of multiple health problems such as obesity, inflammatory bowel disease (IBD) [1], as well
as cardiovascular [2–4], and metabolic diseases [5,6]. Prolonged exposure to this diet has also been
associated with multiple vitamin and mineral deficiencies, including magnesium and calcium [7,8].
Across both Europe [9] and the U.S. [10], it has been repeatedly shown that adults are not meeting the
recommended daily intake levels of both of these minerals, and more specifically in Ireland, the older
population have been demonstrated to be particularly at risk [11]. Deficiencies in magnesium and
calcium have been linked with an increased risk of malnutrition, cardiovascular disease [7,12], type 2
diabetes [13], decreased bone mineral density [14,15] and some cancers [16,17]. Conversely, mounting
evidence suggest that dietary supplementation with these nutrients has a role to play in a healthy
ageing process [8].
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A Western diet has also been shown to markedly decrease the diversity of the gut microbiota, which
is the population of intestinal bacteria that contribute to healthy gastro-intestinal functioning [18,19].
It also negatively impacts upon the immune system [20], the cardiovascular system [21], the brain, and
behaviour [22]. There have been a considerable number of reports in recent years demonstrating that
the composition of the microbiome can significantly impact not only an individual’s risk of systemic
disease [22–24], but also the extent of disease progression [25–28]. It has been demonstrated that
modulating the microbial composition may be a promising therapeutic avenue [29] for cancer [30],
auto-immune [31,32], cardiovascular and kidney diseases [33,34]. Growing evidence suggests that
modulating the diversity of the gut microbiota through dietary intervention (e.g., consuming a
Mediterranean diet) can promote gut health and by extension systemic and brain health [35].
More specifically, several publications have postulated a link between the composition of the gut
microbiota and the absorption of key minerals in the body including calcium and magnesium [36–39].
A seaweed-derived functional food ingredient, which is rich in bioactive calcium and magnesium,
as well as 72 other trace minerals (Aquamin-F™), has previously been shown to have anti-inflammatory
and other health benefits in terms of bone [40,41] and digestive health [42,43], as well as an ability to
lower serum cholesterol levels in humans [44]. The potential benefits of a natural seawater-derived
food ingredient (Aquamin-Mg2+™), which provides increased bioavailable magnesium levels for
gut health has not yet been studied. The aim of this study was thus to investigate the effects of
supplementation of these two functional food ingredients from marine sources (Marine Mineral Blend
(MMB)), which in combination provide high levels of bioactive calcium and magnesium (see Table 1),
on the diversity of the gut microbiota in adult rats.
Table 1. Mineral composition of marine mineral blend. ppm, parts per million.
(>5 ppm) ppm (<5 ppm) ppm (<1 ppm) (<0.2 ppm)
Calcium 285,000 Iodine 4.75 Hafnium Rhodium
Magnesium 214,650 Barium 4.62 Cadmium Tin
Carbon 106,500 Chromium 4.33 Antimony Gallium
Sulfur 3174 Copper 3.73 Bismuth Europium
Sodium 2835 Fluoride 2.97 Gold Holmium
Chloride 1451 Zinc 2.77 Lithium Terbium
Strontium 1262 Cerium 2.13 Selenium Lutetium
Iron 975.50 Silver 2.07 Tellurium Thulium
Silicon 380.00 Neodymium 1.92 Thallium Rubidium
Aluminum 270.00 Lanthanum 1.66 Dysprosium Tantalum
Manganese 265.35 Molybdenum 1.62 Praseodymium Germanium
Potassium 142.60 Arsenic 1.47 Gadolinium Cesium
Boron 110.80 Scandium 1.37 Erbium Mercury
Phosphorus 96.65 Cobalt 1.24 Palladium Platinum
Titanium 23.65 Nickel 1.19 Samarium Iridium
Zirconium 10.45 Beryllium 1.10 Lead Osmium
Vanadium 9.64 Ruthenium 1.10 Ytterbium Rhenium
Thorium 9.08 Indium
Niobium 6.25
Tungsten 5.57
Yttrium 5.47
2. Results
2.1. MMB Supplementation Had No Effect on Weight Gain, Food Intake or Locomotor Activity
MMB-supplementation for six weeks did not significantly affect weight gain (F (2,27) = 0.96,
p = 0.4; Figure 1A) or food intake (F (2,5) = 1.44, p = 0.36; Figure 1B) in rats when compared with body
weight and food intake at the start of the study (week 0 (W 0)). MMB-supplementation had no effect on
general locomotor activity in the open field, measured by either total distance (F (2,27) = 0.05, p = 0.95;
Figure 1C) or velocity travelled (F (2,29) = 1.2, p = 0.31; Figure 1D).
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Figure 1. The effect o MMB supplementation (A) weight gain and (B) fo d inta e course of
the experiment. Gen ral locomotor activity was measured in the open field us ng (C) distance trav lled
and (D) velocity travelled. Data are expressed as mean ± SEM (n = 10).
2.2. MMB Supplementation Increased the Diversity of the Gut Microbiota
There was a significant difference in the total number of observed species of bacteria measured
by 16S rRNA gene sequencing between all groups (H (10.95), p = 0.004; Figure 2A). Post hoc analysis
revealed that the MMB-0.1% suppl mented group contained significantly more bacterial species than
the control group (p < 0.01). The Chao1 index, which reflects species richnes , also showed th t there
were significant differ nces between groups (H (8.1), p = 0.01; Figure 2A). Post hoc analysis rev aled
that this was caused by a significant increase in species in the MMB-0.1% supplemented group when
compared to control (p < 0.05).
Permutational multivariate analysis of variance (PERMANOVA) analysis revealed a significant
difference in beta-diversity between the groups (p = 0.014; Figure 2B). The principal component analysis
(PCA) plot shows that the samples are separating based on MMB supplementation with data from the
control group and both supplemented groups clustering together.
Differences in the relative abundance betw en the groups were seen at all taxonomic levels. At the
phylum level, th e was a reduct on in TM7 in the MMB-0.1% supplemented group when compared to
both the control group and the MMB-0.2% supplemented group. Increased levels of Proteobacteria
were also evident in rats in both supplemented groups. Additionally, there was a greater abundance of
RF3 observed in rats from both supplemented groups when compared to rats in the control group.
These differences at phylum level are reflected at lower taxonomic levels, as shown in Figure 3A,B.
The significantly different taxa are shown in bold. This is particularly apparent at genus level with
differences in several genera highlighted in Figure 3C.
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Figure 3. Relative abundance of caecal microbiota communities at the (A) Phylum level, (B) Family
level, and (C) Genus level in male Sprague Dawley rats fed with a diet supplemented with 0.1%, 0.2%
MMB or a stan ard rat chow (n = 10) for 6 weeks. Only major taxonomic groups are shown. Significant
differences are highlighted in bold. Statistical sign ficance was accepted at p < 0.05. All p values were
corrected for multiple comparisons using the Benjamini-Hochberg False Discovery Rate (pFDR).
2.3. MMB Supplementation Altered the Short Chain Fatty Acid (SCFA) Profile in the Gut
There was no significant difference between the total number of SCFA present in caecal content in
each group (F (2,29) = 0.97, p = 0.39; Figure 4A). MMB-supplementation had no effect on amounts of
acetate (F (2,29) = 1.35, p = 0.28; Figure 4B) or iso-butyrate (F (2,29) = 2.15, p = 0.14; Figure 4E) presented.
However, one-way analysis of variance (ANOVA) indicated that there was a statistically significant
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difference in amounts of propionate (F (2,29) = 4.36, p = 0.02; Figure 4C) and butyrate (F (2,29) = 4.46,
p = 0.02; Figure 4D) presented between groups. Post hoc analysis revealed that this was caused by a
significant increase in amount of propionate in the caecal content of MMB-0.1% supplemented rats
compared to control (p < 0.05), and a significant increase in amount of butyrate in the caecal content of
MMB-0.1% supplemented rats when compared to the MMB-0.2% supplemented group (p < 0.05).
3. Discussion
This study investigated the dose-dependent effects of dietary supplementation of a combination
of a seaweed-derived and seawater-derived functional food ingredient with high levels of bioactive
calcium and magnesium on gut microbiota composition in adult male rats. We found that incorporation
of the supplement into the standard chow of rats resulted in an acceptable and palatable food product,
as there were no differences in either the amount of food eaten or body weight gain between groups
over the course of the experiment. Moreover, there was no impact on general activity as there were no
differences in behaviour in the open field paradigm.
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(D) butyrate and (E) iso-butyrate. Data are expressed as ean ± SEM (n = 10). * p < 0.05 vs. control
group, # p < 0.05 vs MMB-0.2% group.
We report that six weeks of dietary supplementation with this MMB resulted in a significant
increase in gut microbial di compared to control animals. Alter d gut micr biota profiles and
decreases i microbial diversity are evident in and may play a role in the pathophysiology of several
immune and metabolic disorders [45] as well as in neurological and psychiatric disorders [22]. It should
be noted, however, that an impaired biodiversity in the gastrointestinal microbiota is one of a myriad
of health implications associated with these disorders, and it is not inconceivable that an increase in the
bacterial spectrum may be associated with a detrimental health impact in certain circumstances. Several
previous studies have shown that calcium supplementation results in increased gut microbial diversity
in mice [46,47]. Moreover, magnesium-deficient diets have been shown to adversely affect gut microbial
composition, and to promote both anxiety- and depressive-like behaviour in mice [48,49]. However,
there is little evidence to date on the effects of magnesium supplementation on gut microbial diversity.
In the present study, there were also significant changes observed in the gut microbiota composition
at phylum, family and genus levels with many differences in relative abundance noted between the
control group and both MMB supplemented groups. The phylum TM7 decreased from 0.29% of relative
abundance in the caecal contents of the control group to 0.08% in the MMB-0.1% supplemented group,
and increased to 0.31% in the MMB-0.2% supplemented group when compared with the MMB-0.1%
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supplemented group. This phylum has been associated with periodontitis, vaginosis and IBD [50].
Additionally, a high diversity of TM7 has been reported in patients with Crohn’s disease and IBD, and
this phylum has been associated with mucosal inflammatory disease [51]. The relative abundance of
Proteobacteria increased from 0.37% in the control group to 0.53% in the MMB-0.1% supplemented
group, and significantly increased to 0.87% in the MMB-0.2% supplemented group. Proteobacteria
have been linked to inflammation and metabolic syndrome and are usually found in low abundance
in the gut of healthy individuals. Interestingly, it has been suggested that the increased prevalence
of Proteobacteria is an indication of dysbiosis [52] and thus the constituent concentration of food or
supplement ingredients that may potentially affect their abundance should be considered carefully.
The phylum RF3 increased significantly between the control group and the MMB-0.2% supplemented
group, however, it was present at very low levels (0.000034% to 0.011%). It is a candidate division,
thus, no information is currently available on whether this phylum is beneficial or detrimental to
gut health.
The level of Ruminococcaceae, which is one of the most abundant bacterial families in the
mammalian gut and has been associated with the maintenance of gut health [53], was significantly
increased in the caecal contents of MMB-0.2% supplemented group when compared to the control
group. Specifically, Ruminococcaceae increased from 20% in relative abundance in the control group
to 24% in the MMB-0.1% supplemented group and to 27% in the MMB-0.2% supplemented group.
Members of this family are also involved in the degradation of indigestible carbohydrates which can
then be converted to SCFAs [53]. An increase in the level of Christensenellaceae was also observed
in the caecal contents of both of the MMB supplemented groups compared to the control group.
This family increased 30-fold from the control group to the MMB-0.2% supplemented group (0.04%
to 1.2%). It has been associated with a lean body mass index (BMI) and is enriched in the gut of
healthy individuals. Members of this family have also been shown to promote a lean phenotype
after microbiota transplant [54]. Additionally, a higher relative abundance of Porphyromonadaceae
was observed in the MMB supplemented groups when compared to the control group. This family
increased from 0.8% in the control group to 1.28% in the MMB-0.1% supplemented group, and then
showed a further increase to 1.72% in the MMB-0.2% supplemented group. It has been suggested that
members of the Porphyromonadaceae family are important for mediating gut health [55]. Furthermore,
Porphyromonadaceae has been shown to have a protective effect on gut health after antibiotic
treatment [56].
MMB-supplementation also resulted in a significant difference in the composition of SCFAs
present in the gut of rats supplemented with 0.1% MMB, specifically leading to an increase in
the concentration of butyrate and propionate. SCFAs are produced as a result of fermentation of
carbohydrates by the resident bacterial microbiota [57,58], and so they can be directly linked to the
changes in microbial diversity and composition. Growing evidence points to SCFAs having a wide
variety of beneficial functions within the host, including working as signaling molecules and sources of
energy as well as affecting immune function, lipid metabolism and gut integrity [59]. More specifically,
butyrate and propionate have been shown to exert potent anti-inflammatory effects on the gut as well as
decreasing oxidative stress and carcinogenesis [60–62]. Interestingly, this is in line with previous reports
demonstrating anti-inflammatory effects of Aquamin-FTM in both lipopolysaccharide-stimulated,
glial-enriched cultures of cortex and in macrophages [63,64]. Conversely, decreased levels of intestinal
SCFA have been directly correlated with a high-fat, high-sugar diet and associated altered gut microbial
profile as well as with gut micro-inflammation [65]. Butyrate-producing species in the gut include
Ruminococcaecae and Clostridaceae [61], both of which were significantly increased as a result of
MMB supplementation.
For humans, the European Food Safety Authority (EFSA) advises an adequate intake for
magnesium to be 300 mg/day for females and 350 mg/day for males (EFSA Panel on Dietetic Products
and Allergies, 2015), while the recommended daily allowance (RDA) set by the US Institute of Medicine
is 310–320 mg/day for females and 400–420 mg/day for males (Institute of Medicine, 2006). By these
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standards, the dose of magnesium used in the current study is relatively high. Indeed, high levels
of magnesium have been shown to cause reversible osmotic diarrhea in humans [66]. We observed
occasional incidents of diarrhea in rats on the 0.2% MMB supplement in the current study, thus this may
be a reason why the 0.2% MMB supplemented diet did not show the same microbial compositional
changes as the lower dose. Notwithstanding, in this proof-of-concept study in rats, the doses of
magnesium which would have good potential bioavailability were selected based on a previous
pioneering study which showed increased brain bioavailability of magnesium without any adverse
effects. Indeed, enhanced cognitive changes were reported in the rats in this study [67]. Moreover,
a recent review has highlighted that the solubility, dose and food matrix influence the availability of
magnesium [68]. We cannot confirm that magnesium alone however is responsible for the observed
effects in the current study due to its combination with >70 other trace natural minerals. It has been
reported that when a mineral is supplemented in isolation, it is incapable of providing the same
benefits as when that mineral is supplemented in concert with other complementary minerals [69].
This suggests that the marine magnesium component of MMB is enhanced by the full marine mineral
profile in this functional food ingredient. We have shown that MMB-0.1% is tolerated well by rats and
that it enhanced the microbial diversity, which can subsequently play a role in increased bioavailability
through metabolic interactions [70]. Future research will determine the bioavailability of MMB relative
to other magnesium salts and supplements.
In conclusion, we have shown that dietary supplementation with a seaweed and seawater-derived
functional food ingredient rich in bioactive calcium and magnesium as well as more than 70 other
trace elements, significantly enhanced the microbial diversity and composition of SCFAs in the gut
of adult male rats. Given the significant effect of gut microbiota on systemic and brain health, these
results position this marine mineral blend as a promising health promoting functional food ingredient.
It should be noted, however, that research in this field is in its infancy. and there are as yet no definitive
studies showing that a reversion of the narrowing of the microbial spectrum improves health outcomes
in the long term. We propose that our current results contribute to the knowledge needed for the
development of therapeutics for systemic diseases and will also establish a platform from which the
effects of marine-derived compounds on systemic health can be investigated.
4. Materials and Methods
4.1. Dietary Supplementation and Experimental Design
Experimental chow was formulated by supplementing standard chow with a 50:50 mix of
Aquamin FTM (a mineral-rich food ingredient AquaminTM, Marigot Ltd., Cork, Ireland, FDA
GRAS000028; isolated from the red algae Lithoamnion species) and Aquamin-Mg2+TM (enhanced
with natural seawater-derived Mg2+) (Marigot Ltd., Cork, Ireland) to give either an additional 1 g
magnesium/kg diet (Teklad Global custom diet, Envigo, Indianapolis, IN, USA), which equates to
50 mg magnesium/kg body weight per day; or an additional 2 g magnesium/kg diet, which equates
to an additional 100 mg magnesium/kg body weight in an average 40 g rat. The lower-dose paradigm
increased the total magnesium content × 1.5 fold, while the higher dose increased the magnesium
content × 2 fold compared to the magnesium content in the standard chow. For simplicity, the term
Marine Mineral Blend (MMB) is used here to indicate the experimental diets (see Table 1 for the
complete mineral profile of MMB). The concentrations of magnesium formulated in MMB to be
supplemented into the chow, were based on that used in a previous study which showed increased
brain bioavailability of magnesium and associated cognitive functional changes without any adverse
effects [67]. All of the mineral concentrations in the chow were approved by a nutritionist for safe
consumption by rats (Envigo, USA).
Adult male Sprague Dawley rats (approximately 7–8 weeks of age, Envigo, Ely, UK) were
maintained on a 12 h:12 h light: dark cycle (lights on at 08.00 h) under regulated temperature
(21 ± 2 ◦C) and humidity (30–50%), with food and water available ad libitum. Animals were randomly
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divided into three groups and group housed with access to either standard rat chow (n = 10), 0.1%
MMB-supplemented chow (n = 10) or 0.2%-supplemented MMB (n = 10). Animals were allowed free
access to either control or MMB diets for 6 weeks before assessment of general locomotor activity
in the open field. Body weight and food intake were recorded on a weekly basis for the duration
of the study. Food intake was recorded as that in the last week of the experiment expressed as a
percentage of total food intake of the first week of the experiment. The caecal content was collected
at sacrifice after 6 weeks of dietary supplementation. All experiments were conducted in accordance
with the European Directive 2010/63/EU, under an authorisation issued by the Healthcare Products
Regulatory Authority Ireland (HPRA, AE19130/P021) and approved by the Animal Ethics Committee
of University College Cork.
4.2. Open Field
Animals were placed in a white, round arena (90 cm in diameter) and their behaviour was
recorded for 10 min. Motor activity including distance and velocity travelled were measured using
Ethovision XT software (Version 11, Noldus, Leesburg, VA, USA). The apparatus was cleaned with
70% ethanol between each test to remove odour cues. One week after the open field test was carried
out, animals were culled by decapitation. Caecal contents were snap frozen and stored at −80 ◦C
until processing.
4.3. DNA Extraction
DNA extraction was performed as previously described [71]. DNA was extracted using the
QIAmp Fast DNA Stool Mini Kit (Qiagen Ltd., Manchester, UK) according to manufacturer’s
instructions, with the addition of an initial 3 min vortex step using 2 ml screw-cap tubes (Sarstedt,
Wexford, Ireland) containing 0.25 g of a 1:1 mix of 0.1 mm and 1.5 mm diameter sterile zirconia beads
plus a single 2.5 mm diameter bead (BioSpec Products, Bartlesville, OK, USA). Briefly, 200 mg of each
caecal sample was added to a screw-cap tube containing beads with 1 ml of Qiagen InhibitEX® Buffer
(Qiagen, Manchester, UK) and vortexed for 3 min. Samples were incubated at 70 ◦C for 5 min for cell
lysis and then centrifuged. Pelleted DNA was treated with proteinase K, the DNA was washed with
buffers AW1 and AW2, and eluted in 200 µL Buffer ATE. DNA was quantified using the Qubit™ 3.0
Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high sensitivity DNA quantification assay
kit (Bio-Sciences, Dublin, Ireland).
4.4. 16S Compositional Sequencing
The V3-V4 region of the 16S rRNA gene was amplified and prepared for sequencing according
to the 16S Metagenomic Sequencing Library Protocol (https://www.illumina.com/content/dam/
illumina-support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf).
The protocol involved two PCR reactions on the extracted DNA. Firstly, the DNA was
amplified using primers specific to the V3-V4 regions of the 16S rRNA gene: (forward
primer 5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG; reverse
primer 5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC).
Each reaction contained 2.5 µL genomic DNA, 5 µL forward primer (1 µM), 5 µL reverse primer
(1 µM) and 12.5 µL 2X Kapa HiFi Hotstart ReadyMix (Roche Diagnostics Ltd., West Sussex, UK). PCR
amplification was carried out using the following program: 95 ◦C × 3 min, 25 cycles of 95 ◦C × 30 s,
55 ◦C × 30 s, 72 ◦C × 30 s, 72 ◦C × 5 min and held at 4 ◦C. PCR products were visualised using gel
electrophoresis and then purified using AMPure XP beads (Labplan, Kildare, Ireland). Following
this, a second PCR reaction was carried out on the purified DNA using two indexing primers per
sample (Illumina Nextera XT indexing primers, Illumina Netherlands BV, Science Park, Eindhoven
5080, The Netherlands). Each reaction contained 5 µL purified DNA, 5 µL index 1 primer (N7xx), 5 µL
index 2 primer (S5xx), 25 µL 2× Kapa HiFi Hot Start Ready mix (Roche Diagnostics, West Sussex, UK)
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and 10 µL PCR grade water. PCR amplification was completed using the previous program, with only
eight amplification cycles instead of 25. PCR products were visualised and purified as described above.
Samples were quantified using the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along with
the high sensitivity DNA quantification assay kit and then pooled in an equimolar fashion (20 nM).
The sample pool was prepared following Illumina guidelines and sequenced on the MiSeq sequencing
platform in Clinical Microbiomics, Denmark using standard Illumina sequencing protocols.
4.5. Short-Chain Fatty Acid (SCFA) Analysis
SCFA analysis was performed as previously described [72] with some modifications.
Approximately 0.2 g caecal content was mixed with 1.5 mL acidified Milli-Q water, this was vortexed
well for 5–10 min and allowed to stand for 10 min at room temperature. The sample was then
centrifuged at max speed for 5 min and the supernatant was filtered into fresh Eppendorfs using 0.2 µm
filters. The filtered supernatant was then added to 10 mmol/L of internal standard (2-ethylbutyric acid
(2-ETBA)). This was vortexed and centrifuged for 3 min before it was added to a fresh vial containing
an insert. Samples were run in duplicate. Standard solutions containing 10.0, 8.0, 4.0, 2.0, 1.0, 0.5 and
0.1 mmol/L of a fatty acid mix containing iso-valeric acid, valeric acid, acetic acid, propionic acid,
iso-butyric acid and butyric acid were used for calibration. The concentration of SCFA was measured
using a Varian 3800 GC flame-ionisation system (Aquilant, Dublin 22, Ireland), fitted with a ZB-FFAP
column (30 m × 0.32 mm × 0.25 µm; Phenomenex, Cheshire, UK). Helium was used as the carrier gas
at a flow rate of 1.3 mL/min. The initial oven temperature was 100 ◦C for 0.5 min, raised to 180 ◦C
at 8 ◦C/min and held for 1 min, then increased to 200 ◦C at 20 ◦C/min, and finally held at 200 ◦C
for 5 min. The temperatures of the detector and injector were set at 250 ◦C and 240 ◦C, respectively.
Peaks were integrated by using the Varian Star Chromatography Workstation version 6.0 software.
Standards were included in each run to maintain the calibration.
4.6. Bioinformatic Analysis
Resulting 300 bp paired-end reads were assembled using FLASH (FLASH: fast length adjustment
of short reads to improve genome assemblies; [73]). Further sequence read processing was performed
using QIIME (Version 1.8.0) including quality filtering based on a quality score of >25 and
removal of mismatched barcodes and sequences below length thresholds (QIIME allows analysis
of high-throughput community sequencing data). Denoising, chimera detection and clustering into
operational taxonomic units (OTUs) (97% identity) were performed using USEARCH (Version 7,
64-bit, [74], search and clustering orders of magnitude faster than BLAST). OTU sequences were
aligned using PyNAST (PyNAST: python nearest alignment space termination; [75], a flexible tool for
aligning sequences to a template alignment) and taxonomy was determined using the SILVA SSURef
database release 111 [76] at 97% similarity. Alpha diversity estimates were calculated using QIIME.
Beta diversity was calculated using Bray-Curtis based multidimensional scaling (MDS) analysis of
caecal microbiota.
4.7. Statistical Analysis
All data were analyzed using either Statistica (Version 11, Statsoft, OK, USA) or R-3.3.1 ([77],
accessed online) and graphed using GraphPad Prism (Version 5, La Jolla, CA, USA). Data are expressed
as mean± the standard error of the mean (SEM). Data were tested for normality, and statistical analysis
was performed using one-way ANOVA for parametric data or Kruskal-Wallis for nonparametric data,
followed by a post-hoc Dunn’s test if the ANOVA indicated significance. Differences were considered
significant at p < 0.05. The vegan package was used for Bray-Curtis based MDS analysis, and the
Adonis function in vegan was used for PERMANOVA in beta diversity. The Kruskal-Wallis test was
used to identify significant differences between the groups, and the p-values were adjusted using the
Benjamini-Hochberg method (FDR < 0.05).
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